Background/Aims: CTLA-4 polymorphisms are associated with susceptibility to various cancers, but the results are often conflicting. Hence, we performed a comprehensive metaanalysis to quantitatively investigate the association between CTLA-4 polymorphisms (rs231775, rs4553808，rs5742909, rs3087243 or rs733618) and cancer risk. Methods: Data were collected from PubMed and Web of Science. A total of 67 case-control studies were selected for quantitative analysis. Stata (Version 12) software was used to calculate the odds ratio (OR) and 95% confidence interval (CI) to evaluate the strength of the associations. Subgroup meta-analysis was conducted based on ethnicity and cancer type. Heterogeneity tests, sensitivity analysis, and publication bias assessments were also performed. Results: rs231775, rs4553808 and rs5742909 but not rs3087243 and rs733618 were significantly related to cancer risk. In analyses stratified by ethnicity, both rs231775 and rs4553808 were significant susceptibility polymorphisms in an Asian population but not in a Caucasian population. Moreover, there were stronger associations between the rs231775 polymorphism and increased risk of bone, breast, liver, head and neck and pancreatic cancers. Additionally, rs4553808 was associated with significantly increased susceptibility to breast cancer and head and neck cancer. Conclusion: rs231775, rs4553808 and rs5742909 may be used as predictive genetic biomarkers for cancer predisposition. Combined detection of CTLA-4 SNPs could be a useful tool for prediction of cancer susceptibility in clinical practice.
Association of Five SNPs in

Introduction
Worldwide, cancer is a major health problem and one of the leading causes of death [1] . Although considerable advancements have been developed for decades, the increasing 
Results
Study Characteristics
Based on the above selection criteria, a total of 67 eligible studies were included in the current meta-analysis. For rs231775, 64 studies involved a total of 23617 cases and 27261 controls [10] [11] [12] [13] [14] [15] . Moreover, there were 30 studies with 9675 cases and 9623 controls for rs3087243 [12-15, 17, 20, 23-25, 27-29, 31, 32, 35, 37, 40, 41, 44, 45, 47, 53, 54, 61, 63, 65, 66, 73-75] . Additionally, rs4553808 was in 17 studies [12, 14, 15, 23, 28, 29, 31, 37, 41, 44, 47, 49, 51, 52, 62, 73, 76] , rs5742909 was in 32 studies [12, 14, 15, 20, 21, 24, 25, 28-30, 32, 34, 35, 39-41, 45, 47, 52-54, 56, 57, 59, 62, 63, 65, 66, 70, 73, 76, 77] , rs733618 was in 14 studies [13, 23, 28, 37, 44, 47, 51, 52, 62, [73] [74] [75] [76] 78] , and they were analysed. Of the 67 studies, 9 presented a significant deviation from HWE (5 studies on rs231775 [11, Table 6 .
Association between CTLA-4 rs4553808 and cancer susceptibility
For CTLA-4 -1661 A/G, the polymorphism is an A→G change. The association between rs4553808 and cancer risk was analysed in 12 studies with 3635 cases and 4104 controls. In Table 7 .
Association between CTLA-4 rs5742909 and cancer susceptibility For CTLA-4 -318 C/T, the polymorphism is a C→T change. We analysed the association between rs5742909 and cancer susceptibility in 29 studies with 7741 cases and 9611 controls. As a result, we observed a significantly increased cancer risk under the homozygote and recessive models (CT versus CC: OR = 1.30, 95% CI: 1.09-1.56; CT/TT versus CC: OR = 1.33, 95% CI: 1.08-1.65). In the subgroup analysis by cancer type, our results indicated statistically significant associations between rs5742909 and leukaemia susceptibility under all the genetic models. rs5742909 was statistically associated with head and neck cancer susceptibility in the allele model (T vs C: OR = 1.60, 95% CI: 1.23-2.08), the homozygote model (CT vs CC: OR = 1.62, 95% CI: 1.20-2.17) and the recessive model (CT/TT vs CC: OR = 1.67, 95% CI: 1.25-2.23). In the subgroup analysis by ethnicity, similar to the overall analyses, the rs5742909 polymorphism was in significant association with cancer risk in Caucasians under the homozygote and dominant models. Nevertheless, for Asian populations, Table 8 for all the genetic models.
Association between CTLA-4 rs3087243 or rs733618 and cancer susceptibility
For CTLA-4 CT60 A/G, the polymorphism is an A→G change, and for CTLA-4 -1722 T/C, the polymorphism is a T→C change. The analysis between CTLA-4 rs3087243 or rs733618 and cancer susceptibility is shown in Table 9 -10. In general, we did not find a significant association between rs733618 and cancer susceptibility in any genetic model. Moreover, no statistical evidence was observed between the rs733618 polymorphism and cancer risk in the subgroup analysis of cancer type or ethnicity. When analysing rs3087243, we did not 
Sensitivity analyses and publication bias.
A sensitivity analysis was conducted by sequentially excluding each study, and all the results were not essentially altered, suggesting that the results were statistically stable. Fig.  2 shows the plot of the sensitivity analysis for evaluating the association between rs5742909 and cancer risk in the allele model (T vs C). Publication bias of the eligible literature was evaluated by funnel plots and Egger's test. The results indicated the absence of publication bias in the present meta-analysis.
Discussion
CTLA-4 is significant for tumours to evade host immune surveillance and is implicated in immune dysregulation of various cancers [79] . Single nucleotide polymorphisms are the most common form of genetic variations, altering the expression level and/or function of any gene, thereby affecting an individuals' risk of cancer. The CTLA4+49 A allele (rs231775) has Isitmangil (21) Tupikowski (20) Jaiswal (25) Hui (24) Bharti (28) Liu (12) Gokhale (30) Khorshied (32) Feng (29) Yang (39) Karabon (35) Karabon (40) Liu (41) Jiang (73) Bouwhuis (54) Pawlak (53) Rahimifar (52) Ivansson (77) Gogas ( Fang et al.: CTLA-4 SNPs and Cancer Susceptibility a higher mRNA efficiency and an increased CTLA-4 production than the 49G allele [80] . CTLA rs733618 and rs4553808 are located in the promoter region of CTLA4, which may change the motif of the functional DNA binding sites and thus impact the regulation of transcription and alternative splicing and could promote the expression of cell surface CTLA-4 [23, 81] . CTLA4-318C/T (rs5742909) has a higher promoter activity, which may affect the protein formation by increasing the transcription of CTLA-4 mRNA and the expression of CTLA-4 protein [52] . CTLA-4 rs3087243 affects the proportion of the soluble isoform of CTLA-4 that is membrane bound (m)CTLA-4 [82] . Some studies reported associations between CTLA-4 polymorphisms and increased cancer risk. However, the study results are not consistent. Hence, in order to resolve the conflict, we conducted this meta-analysis of the associations between the CTLA-4 rs231775, rs4553808, rs5742909, rs3087243 and rs733618 polymorphisms and cancer risk.
In the present meta-analysis, our results provide evidence that rs231775, rs4553808 and rs5742909 but not rs3087243 and rs733618 contribute independently to cancer susceptibility. In the subgroup analysis by cancer type, the results indicated that individuals with rs231775 had a significantly increased risk of bone cancer, breast cancer, liver cancer, head and neck cancer and pancreatic cancer, while rs4553808 was associated with significantly increased susceptibility to breast cancer and head and neck cancer. For 231775 and 4553808, we also found that they were susceptible to cancer in an Asian population but not in a Caucasian population. We speculate that there are two reasons to explain the difference. First, the different genetic backgrounds may contribute to divergence because the distribution of the CTLA-4 allele frequency varies among Asians and Caucasians [21] . Second, the different populations have various lifestyles and are influenced by different environmental factors.
Previous meta-analyses have discussed the association of CTLA-4 polymorphisms with cancer risk [83] [84] [85] . To the best of our knowledge, we are the first to perform such a comprehensive meta-analysis of the common functional polymorphisms of the CTLA-4 gene comprising all the published and well-defined case-control studies. Compared with the previous studies, our study was more powerful, and we performed more detailed analyses to prove our results. First and most obviously, more eligible studies and a larger sample size were included, indicating that our estimate of the relationship between the CTLA-4 gene SNPs and cancer risk is relatively more accurately. Second, the number of enrolled SNPs in our study was also much higher than that in any other study. In our study, we selected 5 CTLA-4 SNPs, which was more than that any other study, and this was conducive to a more comprehensive understanding the associations between the CTLA-4 polymorphisms and cancer susceptibility. Third, stratified analyses were performed based on Asians and Caucasians, which was in favour of a more general understanding of the associations in diverse populations. Finally, and most importantly, to the best of our knowledge, we are the first to report a significant association of rs231775 and rs4553808 with head and neck cancer susceptibility.
Despite the advantages of a large sample size and the stratified analyses, the metaanalysis had several limitations that should be should be taken into consideration. First, although we reduced the degree of heterogeneity by the stratified analyses based on the cancer type and ethnicity, other sources of heterogeneity were not validated, such as the different genotyping methods. Second, although the total number of studies was large, there were still not enough appropriate studies for us to analyse the subgroups of cancer types, such as liver cancer, renal carcinoma, gastric cancer, bladder cancer, leukaemia, pancreatic cancer or lung cancer. More studies are needed to examine the underlying relationships between the rs4553808 and rs733618 polymorphisms and cancer risk. Third, the standard of the control groups was not uniformly defined. Fourth, due to the lack of some individual data, we were unable to adjust the effect size with possible confounders related with lifestyle risk factors, such as age, obesity, alcohol consumption and smoking. Furthermore, we were unable to examine the interaction between the genetic variables and the environment. Finally, positive reports are inclined to be published, which might cause some bias. 
Conclusion
Our meta-analysis demonstrated that rs231775, rs4553808 and rs5742909 were significantly related to cancer risk. In the stratified analyses by ethnicity, both rs231775 and rs4553808 were significantly associated with susceptibility in an Asian population but not in a Caucasian population. Moreover, there were stronger associations between the rs231775 polymorphism and the increased risk of bone cancer, breast cancer, liver cancer, head and neck cancer and pancreatic cancer. Additionally, rs4553808 was associated with significantly increased susceptibility to breast cancer and head and neck cancer. Furthermore, rs231775 and rs4553808 were first reported as risk factors for head and neck cancer in the metaanalysis. However, large, well-designed epidemiological studies that take into account genegene and gene-environment interactions and have unified genotyping methods, standard healthy control groups, adequate corresponding individual information are needed to validate our results.
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